Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.19 USD

Average target price

53.19 USD

Spread / Average Target

+26.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-16.59%	85.52B
ELI LILLY AND COMPANY	+55.29%	815B
NOVO NORDISK A/S	+45.25%	654B
JOHNSON & JOHNSON	-6.87%	354B
MERCK & CO., INC.	+21.45%	337B
ABBVIE INC.	+10.33%	302B
ASTRAZENECA PLC	+17.68%	247B
ROCHE HOLDING AG	+2.13%	229B
NOVARTIS AG	+12.85%	219B
AMGEN INC.	+9.59%	171B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:22:38 26/06/2024 BST			5-day change	1st Jan Change
42.94 ^USD	+1.79%		+4.28%	-16.59%

06-24	Bristol Myers: accelerated approval in colorectal cancer	CF
06-22	Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	CI

Bristol Myers: accelerated approval in colorectal cancer	06-24	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-22	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	06-21	MT
US FDA approves Bristol Myers' colorectal cancer therapy	06-21	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	06-21	MT
Bristol Myers: application validated for subcutaneous Opdivo	06-21	CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	06-21	CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors	06-19	CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	06-18	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	06-18	MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	06-18	MT
Bristol Myers: Board declares dividend	06-18	CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	06-18	CI
Bristol Myers: FDA approval for treatment	06-14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	06-13	DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	06-13	CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	06-12	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	06-12	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	06-12	CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	06-11
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	06-10	MT
Geron shares surge after U.S. FDA approves blood disorder drug	06-07	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	06-05	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	06-05	CI